Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 46 | 2024 | 5387 | 3.750 |
Why?
|
Lung Neoplasms | 66 | 2024 | 13485 | 3.500 |
Why?
|
Radiosurgery | 22 | 2024 | 1329 | 3.220 |
Why?
|
Radiation Oncology | 6 | 2023 | 571 | 2.100 |
Why?
|
Radiation Pneumonitis | 5 | 2024 | 99 | 1.490 |
Why?
|
Artificial Intelligence | 10 | 2024 | 2662 | 1.420 |
Why?
|
Radiation Injuries | 4 | 2024 | 1194 | 1.350 |
Why?
|
Radiotherapy | 7 | 2024 | 1497 | 1.150 |
Why?
|
Cone-Beam Computed Tomography | 3 | 2020 | 447 | 0.990 |
Why?
|
Heart Diseases | 4 | 2024 | 2817 | 0.960 |
Why?
|
Tachycardia, Ventricular | 7 | 2022 | 1313 | 0.950 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 13 | 2025 | 1667 | 0.910 |
Why?
|
Radiation Dosage | 12 | 2022 | 1957 | 0.790 |
Why?
|
Tumor Burden | 9 | 2020 | 1900 | 0.760 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 269 | 0.740 |
Why?
|
Coronary Vessels | 6 | 2024 | 3100 | 0.710 |
Why?
|
Collagen Diseases | 1 | 2017 | 39 | 0.580 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2020 | 454 | 0.570 |
Why?
|
Urologic Diseases | 2 | 2018 | 246 | 0.570 |
Why?
|
Equipment and Supplies | 1 | 2020 | 273 | 0.560 |
Why?
|
Equipment Failure | 1 | 2018 | 585 | 0.510 |
Why?
|
Neoplasm Staging | 19 | 2024 | 11218 | 0.510 |
Why?
|
Radiotherapy Dosage | 10 | 2024 | 2911 | 0.510 |
Why?
|
Salvage Therapy | 3 | 2018 | 1274 | 0.500 |
Why?
|
Tomography, X-Ray Computed | 21 | 2025 | 20708 | 0.500 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2024 | 794 | 0.490 |
Why?
|
Heart | 5 | 2023 | 4425 | 0.460 |
Why?
|
Neoplasms | 11 | 2024 | 22350 | 0.450 |
Why?
|
Pneumonectomy | 2 | 2018 | 1147 | 0.440 |
Why?
|
Humans | 141 | 2025 | 766766 | 0.430 |
Why?
|
Peanut Hypersensitivity | 3 | 2022 | 217 | 0.430 |
Why?
|
Retrospective Studies | 38 | 2025 | 81635 | 0.420 |
Why?
|
Four-Dimensional Computed Tomography | 3 | 2024 | 140 | 0.420 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2901 | 0.410 |
Why?
|
Pacemaker, Artificial | 1 | 2018 | 828 | 0.410 |
Why?
|
Cystectomy | 2 | 2014 | 603 | 0.400 |
Why?
|
Urinary Bladder | 4 | 2014 | 1155 | 0.380 |
Why?
|
Catheter Ablation | 5 | 2022 | 2786 | 0.360 |
Why?
|
Aged | 49 | 2024 | 171343 | 0.360 |
Why?
|
Muscle, Smooth | 1 | 2014 | 931 | 0.350 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 276 | 0.350 |
Why?
|
Natural Language Processing | 4 | 2023 | 1203 | 0.350 |
Why?
|
Adenocarcinoma | 7 | 2022 | 6359 | 0.340 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2014 | 2184 | 0.330 |
Why?
|
Aged, 80 and over | 24 | 2020 | 59550 | 0.330 |
Why?
|
Vascular Diseases | 1 | 2017 | 1161 | 0.320 |
Why?
|
ras Proteins | 1 | 2014 | 1055 | 0.320 |
Why?
|
Defibrillators, Implantable | 1 | 2018 | 1499 | 0.310 |
Why?
|
Middle Aged | 51 | 2024 | 223257 | 0.310 |
Why?
|
Esophageal Neoplasms | 3 | 2023 | 1660 | 0.310 |
Why?
|
Vulvar Neoplasms | 1 | 2010 | 266 | 0.300 |
Why?
|
Organs at Risk | 3 | 2024 | 365 | 0.290 |
Why?
|
Lung | 10 | 2024 | 10067 | 0.290 |
Why?
|
Male | 62 | 2025 | 364142 | 0.290 |
Why?
|
Uremia | 4 | 1992 | 202 | 0.260 |
Why?
|
Combined Modality Therapy | 8 | 2022 | 8540 | 0.260 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3250 | 0.250 |
Why?
|
Female | 56 | 2025 | 396520 | 0.250 |
Why?
|
Point Mutation | 1 | 2011 | 1591 | 0.250 |
Why?
|
Cardiomyopathies | 3 | 2024 | 2059 | 0.250 |
Why?
|
Models, Statistical | 2 | 2019 | 5091 | 0.250 |
Why?
|
Urethra | 2 | 2018 | 406 | 0.250 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 11872 | 0.240 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7431 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 10384 | 0.230 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2017 | 1762 | 0.230 |
Why?
|
Food Hypersensitivity | 2 | 2022 | 734 | 0.230 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8045 | 0.220 |
Why?
|
Thorax | 2 | 2024 | 555 | 0.220 |
Why?
|
Temporal Muscle | 1 | 2023 | 36 | 0.220 |
Why?
|
Kaplan-Meier Estimate | 6 | 2019 | 6512 | 0.220 |
Why?
|
Hypertension | 2 | 2022 | 8616 | 0.220 |
Why?
|
Algorithms | 11 | 2025 | 14072 | 0.220 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2016 | 2028 | 0.210 |
Why?
|
Growth Charts | 1 | 2023 | 60 | 0.210 |
Why?
|
Carcinoma | 1 | 2014 | 2324 | 0.210 |
Why?
|
Desensitization, Immunologic | 4 | 2022 | 546 | 0.210 |
Why?
|
Mutation | 9 | 2024 | 30213 | 0.210 |
Why?
|
Venous Thromboembolism | 1 | 2016 | 1882 | 0.210 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5368 | 0.200 |
Why?
|
Multivariate Analysis | 6 | 2018 | 12064 | 0.200 |
Why?
|
Preoperative Care | 2 | 2011 | 2253 | 0.200 |
Why?
|
Prostatic Neoplasms | 4 | 2023 | 11094 | 0.200 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4522 | 0.200 |
Why?
|
Coronary Artery Disease | 1 | 2022 | 6558 | 0.200 |
Why?
|
Acrylamides | 1 | 2024 | 260 | 0.200 |
Why?
|
Esophagitis | 1 | 2023 | 163 | 0.190 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2008 | 790 | 0.190 |
Why?
|
Survival Analysis | 4 | 2020 | 10100 | 0.190 |
Why?
|
Rectal Neoplasms | 1 | 2010 | 1183 | 0.190 |
Why?
|
Diagnosis, Computer-Assisted | 2 | 2018 | 698 | 0.190 |
Why?
|
Medical Oncology | 3 | 2023 | 2340 | 0.190 |
Why?
|
Automation | 1 | 2023 | 586 | 0.180 |
Why?
|
Radiation Tolerance | 3 | 2018 | 476 | 0.180 |
Why?
|
Prescriptions | 1 | 2023 | 388 | 0.180 |
Why?
|
Adult | 30 | 2024 | 223307 | 0.180 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2016 | 4049 | 0.180 |
Why?
|
Radiopharmaceuticals | 1 | 2011 | 2704 | 0.180 |
Why?
|
Treatment Outcome | 18 | 2022 | 65273 | 0.180 |
Why?
|
Cefazolin | 1 | 2021 | 94 | 0.180 |
Why?
|
Neoadjuvant Therapy | 5 | 2016 | 2902 | 0.180 |
Why?
|
Calcitriol | 2 | 1992 | 301 | 0.180 |
Why?
|
Imaging, Three-Dimensional | 4 | 2014 | 4047 | 0.180 |
Why?
|
Ribosomal Proteins | 2 | 2017 | 369 | 0.170 |
Why?
|
Fluoroscopy | 2 | 2014 | 948 | 0.160 |
Why?
|
Prognosis | 10 | 2022 | 29948 | 0.160 |
Why?
|
Indoles | 2 | 2024 | 1834 | 0.160 |
Why?
|
Phantoms, Imaging | 4 | 2022 | 2474 | 0.160 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2024 | 8926 | 0.150 |
Why?
|
Neutrons | 1 | 2018 | 78 | 0.150 |
Why?
|
Sarcoidosis | 1 | 2024 | 535 | 0.150 |
Why?
|
Arrhythmias, Cardiac | 4 | 2023 | 2258 | 0.150 |
Why?
|
Sarcopenia | 1 | 2023 | 378 | 0.150 |
Why?
|
Aniline Compounds | 1 | 2024 | 1079 | 0.150 |
Why?
|
Ablation Techniques | 1 | 2021 | 254 | 0.150 |
Why?
|
Laryngeal Neoplasms | 1 | 2022 | 514 | 0.150 |
Why?
|
Respiration | 5 | 2017 | 1654 | 0.150 |
Why?
|
Penicillins | 1 | 2021 | 404 | 0.150 |
Why?
|
Pneumonia | 2 | 2020 | 2159 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2023 | 9404 | 0.150 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2020 | 262 | 0.150 |
Why?
|
Diagnostic Imaging | 3 | 2019 | 3531 | 0.140 |
Why?
|
Body Composition | 2 | 2024 | 2441 | 0.140 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39309 | 0.140 |
Why?
|
Stereotaxic Techniques | 1 | 2020 | 551 | 0.140 |
Why?
|
Pulmonary Veins | 1 | 2023 | 758 | 0.140 |
Why?
|
Larynx | 1 | 2022 | 492 | 0.140 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 795 | 0.140 |
Why?
|
Angina Pectoris | 1 | 2021 | 956 | 0.140 |
Why?
|
Cohort Studies | 7 | 2021 | 41710 | 0.140 |
Why?
|
Death | 1 | 2021 | 685 | 0.130 |
Why?
|
Survival Rate | 4 | 2018 | 12825 | 0.130 |
Why?
|
Carcinoma, Large Cell | 1 | 2016 | 114 | 0.130 |
Why?
|
Electrophysiology | 1 | 2019 | 1263 | 0.130 |
Why?
|
Antibiotic Prophylaxis | 1 | 2021 | 641 | 0.130 |
Why?
|
Antibodies, Monoclonal | 2 | 2024 | 9244 | 0.130 |
Why?
|
Administration, Oral | 6 | 2022 | 4018 | 0.130 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 784 | 0.120 |
Why?
|
Medical Errors | 1 | 2023 | 1260 | 0.120 |
Why?
|
Feasibility Studies | 3 | 2024 | 5306 | 0.120 |
Why?
|
Ribonucleoproteins | 1 | 2018 | 358 | 0.120 |
Why?
|
Cytoplasmic Granules | 1 | 2018 | 574 | 0.120 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6850 | 0.120 |
Why?
|
Osteopontin | 1 | 2017 | 305 | 0.120 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1203 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 392 | 0.120 |
Why?
|
Medical Informatics | 1 | 2021 | 744 | 0.120 |
Why?
|
Quality Assurance, Health Care | 1 | 2025 | 2171 | 0.120 |
Why?
|
Incidence | 6 | 2021 | 21525 | 0.110 |
Why?
|
Immunoconjugates | 1 | 2022 | 976 | 0.110 |
Why?
|
Radiotherapy, Conformal | 1 | 2017 | 545 | 0.110 |
Why?
|
Evaluation Studies as Topic | 1 | 2016 | 1622 | 0.110 |
Why?
|
Risk Factors | 12 | 2024 | 74881 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 6 | 2024 | 36567 | 0.110 |
Why?
|
Radiometry | 2 | 2017 | 812 | 0.110 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2014 | 638 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5690 | 0.110 |
Why?
|
Positron-Emission Tomography | 6 | 2019 | 6550 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 16044 | 0.110 |
Why?
|
Neoplasm Invasiveness | 2 | 2014 | 3609 | 0.110 |
Why?
|
Ribosomes | 1 | 2017 | 496 | 0.110 |
Why?
|
Allergens | 4 | 2022 | 1436 | 0.110 |
Why?
|
Neoplasm Metastasis | 6 | 2022 | 4891 | 0.110 |
Why?
|
Observer Variation | 2 | 2016 | 2614 | 0.110 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 15416 | 0.110 |
Why?
|
Prostate | 2 | 2023 | 1757 | 0.100 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2023 | 3681 | 0.100 |
Why?
|
Reproducibility of Results | 8 | 2024 | 20144 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1134 | 0.100 |
Why?
|
Lung Diseases | 1 | 2023 | 1941 | 0.100 |
Why?
|
Renal Dialysis | 2 | 1992 | 1790 | 0.100 |
Why?
|
GTP-Binding Proteins | 1 | 2017 | 946 | 0.100 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2015 | 1787 | 0.100 |
Why?
|
Drug Hypersensitivity | 1 | 2021 | 903 | 0.100 |
Why?
|
Ubiquitination | 1 | 2017 | 1007 | 0.100 |
Why?
|
Thoracic Wall | 1 | 2014 | 203 | 0.100 |
Why?
|
Ubiquitin | 1 | 2017 | 841 | 0.100 |
Why?
|
Brain Neoplasms | 4 | 2017 | 9101 | 0.100 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 1226 | 0.100 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1673 | 0.090 |
Why?
|
Spinal Neoplasms | 2 | 2025 | 714 | 0.090 |
Why?
|
Pattern Recognition, Automated | 2 | 2014 | 979 | 0.090 |
Why?
|
Lung Diseases, Interstitial | 1 | 2020 | 939 | 0.090 |
Why?
|
Neoplasm Proteins | 3 | 2023 | 3601 | 0.090 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 148 | 0.090 |
Why?
|
Ultrasonography, Prenatal | 1 | 2018 | 1772 | 0.090 |
Why?
|
Stress, Physiological | 1 | 2018 | 1406 | 0.090 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2014 | 878 | 0.090 |
Why?
|
Heart Ventricles | 1 | 2022 | 3832 | 0.090 |
Why?
|
Proportional Hazards Models | 3 | 2015 | 12534 | 0.090 |
Why?
|
Pleural Neoplasms | 1 | 2015 | 584 | 0.080 |
Why?
|
Cold Temperature | 1 | 2013 | 794 | 0.080 |
Why?
|
Erythroid Precursor Cells | 2 | 2008 | 211 | 0.080 |
Why?
|
Prospective Studies | 7 | 2025 | 54871 | 0.080 |
Why?
|
Myocardial Ischemia | 1 | 2020 | 2132 | 0.080 |
Why?
|
Protein Biosynthesis | 1 | 2017 | 2093 | 0.080 |
Why?
|
Palliative Care | 1 | 2025 | 3640 | 0.080 |
Why?
|
Multicenter Studies as Topic | 1 | 2014 | 1733 | 0.080 |
Why?
|
Insulin | 4 | 1992 | 6608 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2015 | 3552 | 0.080 |
Why?
|
RecQ Helicases | 1 | 2009 | 53 | 0.080 |
Why?
|
Parathyroid Hormone | 3 | 1992 | 1791 | 0.080 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 406 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2023 | 2929 | 0.080 |
Why?
|
Hematopoiesis | 2 | 2011 | 2060 | 0.080 |
Why?
|
Mesothelioma | 1 | 2015 | 774 | 0.080 |
Why?
|
Disease Progression | 4 | 2024 | 13640 | 0.080 |
Why?
|
E1A-Associated p300 Protein | 1 | 2009 | 125 | 0.080 |
Why?
|
Calcium | 1 | 2022 | 5783 | 0.080 |
Why?
|
SEER Program | 2 | 2010 | 1443 | 0.080 |
Why?
|
Endpoint Determination | 1 | 2011 | 592 | 0.080 |
Why?
|
Prostatectomy | 1 | 2016 | 1786 | 0.080 |
Why?
|
Spinal Cord Compression | 1 | 2010 | 234 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4747 | 0.080 |
Why?
|
Kidney Failure, Chronic | 4 | 1997 | 2505 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 1 | 2023 | 3186 | 0.070 |
Why?
|
Carbohydrate Metabolism | 1 | 1989 | 261 | 0.070 |
Why?
|
Time Factors | 5 | 2019 | 40149 | 0.070 |
Why?
|
Mortality | 1 | 2019 | 2910 | 0.070 |
Why?
|
ROC Curve | 2 | 2017 | 3620 | 0.070 |
Why?
|
Biosensing Techniques | 1 | 2013 | 640 | 0.070 |
Why?
|
Receptors, Cell Surface | 1 | 2017 | 2815 | 0.070 |
Why?
|
Gene Expression Regulation | 4 | 2011 | 11920 | 0.070 |
Why?
|
Chest Pain | 1 | 2014 | 1101 | 0.070 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2018 | 1481 | 0.070 |
Why?
|
Erythroid Cells | 1 | 2008 | 237 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2023 | 4282 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4114 | 0.060 |
Why?
|
RNA Interference | 3 | 2017 | 2827 | 0.060 |
Why?
|
Fluorescent Dyes | 1 | 2013 | 1927 | 0.060 |
Why?
|
Acute Disease | 1 | 2016 | 7241 | 0.060 |
Why?
|
Vitamin D Deficiency | 2 | 1992 | 1349 | 0.060 |
Why?
|
Canada | 2 | 2022 | 2126 | 0.060 |
Why?
|
Fluorouracil | 1 | 2010 | 1651 | 0.060 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2010 | 776 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2016 | 3468 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5444 | 0.060 |
Why?
|
Cell Differentiation | 5 | 2010 | 11651 | 0.060 |
Why?
|
Radiography, Thoracic | 2 | 2023 | 1320 | 0.060 |
Why?
|
Cytoplasm | 1 | 2009 | 1505 | 0.060 |
Why?
|
Cisplatin | 1 | 2010 | 1655 | 0.060 |
Why?
|
Postoperative Care | 1 | 2010 | 1480 | 0.060 |
Why?
|
Megakaryocytes | 1 | 2008 | 557 | 0.060 |
Why?
|
Erythropoiesis | 1 | 2008 | 692 | 0.060 |
Why?
|
United States | 3 | 2022 | 72951 | 0.060 |
Why?
|
Anemia, Diamond-Blackfan | 1 | 2005 | 147 | 0.060 |
Why?
|
Heart Aneurysm | 1 | 2024 | 114 | 0.060 |
Why?
|
Carrier Proteins | 1 | 2017 | 4924 | 0.050 |
Why?
|
Insulin Resistance | 3 | 1992 | 3989 | 0.050 |
Why?
|
RNA, Messenger | 2 | 2017 | 12791 | 0.050 |
Why?
|
Phenotype | 3 | 2017 | 16724 | 0.050 |
Why?
|
Quality Improvement | 1 | 2018 | 3850 | 0.050 |
Why?
|
Odds Ratio | 2 | 2014 | 9661 | 0.050 |
Why?
|
Silver | 1 | 2023 | 119 | 0.050 |
Why?
|
Glucose | 2 | 1992 | 4340 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4853 | 0.050 |
Why?
|
Thalidomide | 1 | 2008 | 886 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7475 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2011 | 8621 | 0.050 |
Why?
|
DNA Repair | 1 | 2011 | 2050 | 0.050 |
Why?
|
Area Under Curve | 2 | 2016 | 1638 | 0.050 |
Why?
|
Gene Regulatory Networks | 1 | 2011 | 1751 | 0.050 |
Why?
|
Hospitals, Teaching | 2 | 2021 | 1156 | 0.050 |
Why?
|
Cystitis | 1 | 2002 | 96 | 0.050 |
Why?
|
Immunologic Memory | 1 | 2008 | 1377 | 0.050 |
Why?
|
Cachexia | 1 | 2023 | 202 | 0.050 |
Why?
|
Particle Accelerators | 1 | 2022 | 172 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15908 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2902 | 0.050 |
Why?
|
Protein Processing, Post-Translational | 1 | 2009 | 1964 | 0.050 |
Why?
|
Regression Analysis | 1 | 2010 | 6329 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12806 | 0.050 |
Why?
|
Motion | 2 | 2014 | 783 | 0.040 |
Why?
|
British Columbia | 1 | 2021 | 239 | 0.040 |
Why?
|
Nomograms | 1 | 2022 | 235 | 0.040 |
Why?
|
Clindamycin | 1 | 2021 | 138 | 0.040 |
Why?
|
MicroRNAs | 2 | 2008 | 3792 | 0.040 |
Why?
|
Principal Component Analysis | 2 | 2014 | 949 | 0.040 |
Why?
|
Melanoma | 1 | 2019 | 5700 | 0.040 |
Why?
|
Treatment Failure | 3 | 2015 | 2659 | 0.040 |
Why?
|
Infant | 5 | 2022 | 36461 | 0.040 |
Why?
|
Cell Nucleus | 1 | 2009 | 2870 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 2021 | 11513 | 0.040 |
Why?
|
Genotype | 1 | 2014 | 13036 | 0.040 |
Why?
|
Evolution, Molecular | 1 | 2008 | 1892 | 0.040 |
Why?
|
Child, Preschool | 6 | 2022 | 42577 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2017 | 22248 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9602 | 0.040 |
Why?
|
Vitamin D | 2 | 1992 | 3270 | 0.040 |
Why?
|
Forecasting | 1 | 2008 | 2936 | 0.040 |
Why?
|
Self Administration | 1 | 2000 | 386 | 0.040 |
Why?
|
Gene Expression Profiling | 4 | 2011 | 9525 | 0.040 |
Why?
|
Hematopoietic Stem Cells | 2 | 2008 | 3408 | 0.040 |
Why?
|
Tilapia | 1 | 1998 | 24 | 0.040 |
Why?
|
Urethral Obstruction | 1 | 2018 | 56 | 0.040 |
Why?
|
Workplace | 1 | 2005 | 873 | 0.040 |
Why?
|
Camptothecin | 1 | 2022 | 599 | 0.040 |
Why?
|
Protein Transport | 2 | 2018 | 1942 | 0.040 |
Why?
|
Software | 3 | 2021 | 4466 | 0.040 |
Why?
|
Prednisone | 1 | 2023 | 1566 | 0.040 |
Why?
|
Social Environment | 1 | 2023 | 1012 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2018 | 4276 | 0.040 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2022 | 772 | 0.040 |
Why?
|
HeLa Cells | 2 | 2018 | 3073 | 0.040 |
Why?
|
Vancomycin | 1 | 2021 | 504 | 0.040 |
Why?
|
Myelodysplastic Syndromes | 1 | 2008 | 1404 | 0.040 |
Why?
|
Spine | 1 | 2025 | 1134 | 0.040 |
Why?
|
Blood Glucose | 1 | 1992 | 6422 | 0.040 |
Why?
|
Dexamethasone | 1 | 2005 | 1962 | 0.040 |
Why?
|
Health Facilities | 1 | 2022 | 579 | 0.040 |
Why?
|
Epinephrine | 1 | 2020 | 782 | 0.030 |
Why?
|
Skin Tests | 1 | 2019 | 630 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2011 | 5795 | 0.030 |
Why?
|
Heart Failure | 1 | 2021 | 11882 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3796 | 0.030 |
Why?
|
Patient Selection | 1 | 2008 | 4252 | 0.030 |
Why?
|
Growth Hormone | 1 | 1998 | 572 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 859 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2017 | 401 | 0.030 |
Why?
|
Transfection | 2 | 2017 | 5754 | 0.030 |
Why?
|
Adenoviridae | 2 | 2014 | 1093 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2023 | 1998 | 0.030 |
Why?
|
K562 Cells | 2 | 2008 | 645 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2008 | 4784 | 0.030 |
Why?
|
Social Support | 1 | 2005 | 2191 | 0.030 |
Why?
|
Primary Prevention | 1 | 2022 | 1188 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2008 | 4652 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 13643 | 0.030 |
Why?
|
Electronic Health Records | 2 | 2023 | 4880 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 2008 | 7609 | 0.030 |
Why?
|
Antigens, CD34 | 2 | 2008 | 656 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2014 | 6214 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2017 | 957 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2000 | 962 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 2002 | 2730 | 0.030 |
Why?
|
Radiography | 2 | 2014 | 6968 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1594 | 0.030 |
Why?
|
Freezing | 1 | 2013 | 310 | 0.030 |
Why?
|
Learning | 1 | 2022 | 1754 | 0.030 |
Why?
|
Rib Fractures | 1 | 2014 | 124 | 0.030 |
Why?
|
Immunoglobulin E | 1 | 2019 | 1495 | 0.030 |
Why?
|
Time | 1 | 2014 | 550 | 0.030 |
Why?
|
Body Weight | 1 | 2023 | 4626 | 0.020 |
Why?
|
Integrases | 1 | 2014 | 520 | 0.020 |
Why?
|
Erythropoietin | 2 | 2008 | 718 | 0.020 |
Why?
|
Child | 5 | 2023 | 80668 | 0.020 |
Why?
|
Lentivirus | 1 | 2014 | 518 | 0.020 |
Why?
|
Cells, Cultured | 4 | 2008 | 18984 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2021 | 1547 | 0.020 |
Why?
|
Glucose Clamp Technique | 1 | 1992 | 262 | 0.020 |
Why?
|
Pyrimidines | 1 | 2024 | 3043 | 0.020 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2014 | 594 | 0.020 |
Why?
|
Transcription Factors | 1 | 2011 | 12150 | 0.020 |
Why?
|
Stents | 1 | 2023 | 3193 | 0.020 |
Why?
|
Radiology | 1 | 2024 | 2105 | 0.020 |
Why?
|
Mice, Nude | 1 | 2017 | 3616 | 0.020 |
Why?
|
Coronary Disease | 1 | 2005 | 5915 | 0.020 |
Why?
|
Models, Genetic | 1 | 2020 | 3450 | 0.020 |
Why?
|
Hospitalization | 1 | 2010 | 10823 | 0.020 |
Why?
|
Histone Deacetylase 2 | 1 | 2010 | 71 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1889 | 0.020 |
Why?
|
Risk Assessment | 2 | 2024 | 24295 | 0.020 |
Why?
|
Computer Simulation | 2 | 2014 | 6259 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1621 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2011 | 399 | 0.020 |
Why?
|
Hemorrhage | 1 | 2002 | 3464 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 1992 | 1377 | 0.020 |
Why?
|
Histone Deacetylase 1 | 1 | 2010 | 133 | 0.020 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2011 | 428 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 2021 | 1931 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2005 | 4527 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6779 | 0.020 |
Why?
|
Models, Biological | 3 | 2014 | 9461 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3914 | 0.020 |
Why?
|
Animals | 8 | 2018 | 168930 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2000 | 2779 | 0.020 |
Why?
|
Belgium | 2 | 2005 | 119 | 0.020 |
Why?
|
Nuclear Localization Signals | 1 | 2009 | 78 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2017 | 1351 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 1992 | 1180 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2023 | 12430 | 0.020 |
Why?
|
Drosophila melanogaster | 1 | 2018 | 1725 | 0.020 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2014 | 732 | 0.020 |
Why?
|
Hospitals, Rural | 1 | 2010 | 174 | 0.020 |
Why?
|
Platelet Membrane Glycoprotein IIb | 1 | 2008 | 51 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2021 | 3935 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2020 | 3691 | 0.020 |
Why?
|
Hospitals, Urban | 1 | 2010 | 494 | 0.020 |
Why?
|
Hyperparathyroidism | 1 | 1989 | 338 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2013 | 873 | 0.020 |
Why?
|
Anthropometry | 1 | 2013 | 1336 | 0.020 |
Why?
|
Africa | 1 | 2010 | 726 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2008 | 82 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2023 | 4970 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7074 | 0.020 |
Why?
|
Integrin beta3 | 1 | 2008 | 120 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2013 | 1250 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8507 | 0.020 |
Why?
|
Cell Lineage | 2 | 2008 | 2572 | 0.020 |
Why?
|
Radon | 1 | 1989 | 91 | 0.020 |
Why?
|
Stroke Volume | 1 | 2021 | 5618 | 0.020 |
Why?
|
Carbohydrates | 1 | 1989 | 387 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 2629 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2009 | 928 | 0.020 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2008 | 386 | 0.020 |
Why?
|
Propensity Score | 1 | 2014 | 1972 | 0.020 |
Why?
|
Acetylation | 1 | 2009 | 1054 | 0.020 |
Why?
|
Thrombopoietin | 1 | 2008 | 225 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7585 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2823 | 0.020 |
Why?
|
Movement | 1 | 2013 | 1468 | 0.020 |
Why?
|
Mice | 4 | 2017 | 81889 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2010 | 1716 | 0.020 |
Why?
|
Adolescent | 5 | 2018 | 88904 | 0.020 |
Why?
|
Receptor, Insulin | 1 | 1989 | 839 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2014 | 3401 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 4570 | 0.010 |
Why?
|
Stem Cell Factor | 1 | 2005 | 194 | 0.010 |
Why?
|
Anticoagulants | 1 | 2000 | 4855 | 0.010 |
Why?
|
Flow Cytometry | 2 | 2005 | 5890 | 0.010 |
Why?
|
Biological Transport | 1 | 1989 | 2083 | 0.010 |
Why?
|
Lysine | 1 | 2009 | 997 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2008 | 1525 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2014 | 2948 | 0.010 |
Why?
|
Cytokines | 1 | 2019 | 7438 | 0.010 |
Why?
|
Interleukin-3 | 1 | 2005 | 425 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2005 | 861 | 0.010 |
Why?
|
Luciferases | 1 | 2005 | 713 | 0.010 |
Why?
|
Chromosome Deletion | 1 | 2008 | 1384 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2010 | 1374 | 0.010 |
Why?
|
Hodgkin Disease | 1 | 2010 | 1384 | 0.010 |
Why?
|
Retroviridae | 1 | 2005 | 846 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1997 | 4278 | 0.010 |
Why?
|
Boston | 1 | 2015 | 9346 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 2014 | 2561 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 6207 | 0.010 |
Why?
|
Genetic Markers | 1 | 2008 | 2603 | 0.010 |
Why?
|
Adenoviridae Infections | 1 | 2002 | 97 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 13476 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2885 | 0.010 |
Why?
|
Energy Intake | 1 | 1989 | 2142 | 0.010 |
Why?
|
Busulfan | 1 | 2002 | 264 | 0.010 |
Why?
|
BK Virus | 1 | 2002 | 120 | 0.010 |
Why?
|
Therapeutic Irrigation | 1 | 2002 | 297 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2008 | 2413 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10860 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2009 | 3738 | 0.010 |
Why?
|
Tumor Virus Infections | 1 | 2002 | 438 | 0.010 |
Why?
|
Antifreeze Proteins | 1 | 1998 | 12 | 0.010 |
Why?
|
Salmon | 1 | 1998 | 34 | 0.010 |
Why?
|
Aquaculture | 1 | 1998 | 28 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2005 | 3432 | 0.010 |
Why?
|
Metallothionein | 1 | 1998 | 62 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18075 | 0.010 |
Why?
|
Registries | 1 | 2015 | 8351 | 0.010 |
Why?
|
Databases, Factual | 1 | 2014 | 8066 | 0.010 |
Why?
|
International Normalized Ratio | 1 | 2000 | 382 | 0.010 |
Why?
|
Neurons | 1 | 2018 | 9515 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2018 | 26389 | 0.010 |
Why?
|
Energy Metabolism | 1 | 1989 | 2903 | 0.010 |
Why?
|
Down-Regulation | 1 | 2005 | 2931 | 0.010 |
Why?
|
Blotting, Western | 1 | 2005 | 5022 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2009 | 13411 | 0.010 |
Why?
|
Child Development | 1 | 1989 | 2327 | 0.010 |
Why?
|
Pregnancy | 1 | 2018 | 30237 | 0.010 |
Why?
|
Blood Pressure | 1 | 1992 | 8533 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 17608 | 0.010 |
Why?
|
Long-Term Care | 1 | 2000 | 630 | 0.010 |
Why?
|
Up-Regulation | 1 | 2005 | 4142 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13278 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2005 | 2158 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18330 | 0.010 |
Why?
|
Fishes | 1 | 1998 | 607 | 0.010 |
Why?
|
Transplantation Conditioning | 1 | 2002 | 1635 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2011 | 7868 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 9611 | 0.010 |
Why?
|
DNA Primers | 1 | 1998 | 2826 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2000 | 2108 | 0.010 |
Why?
|
Environmental Exposure | 1 | 1989 | 4554 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23619 | 0.010 |
Why?
|
Homozygote | 1 | 1998 | 1775 | 0.010 |
Why?
|
Animals, Genetically Modified | 1 | 1998 | 1562 | 0.010 |
Why?
|
Prevalence | 1 | 2010 | 15835 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 1997 | 2127 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2010 | 5194 | 0.010 |
Why?
|
Stem Cells | 1 | 2005 | 3537 | 0.010 |
Why?
|
Decision Making | 1 | 2005 | 3951 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15563 | 0.010 |
Why?
|
Glycoproteins | 1 | 1998 | 2201 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2000 | 2334 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2005 | 14652 | 0.010 |
Why?
|
Papillomavirus Infections | 1 | 2002 | 1639 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2008 | 22352 | 0.010 |
Why?
|
Colon | 1 | 1997 | 1797 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2005 | 10445 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2002 | 4215 | 0.000 |
Why?
|
Patient Satisfaction | 1 | 2000 | 3485 | 0.000 |
Why?
|
Base Sequence | 1 | 1998 | 12415 | 0.000 |
Why?
|
Promoter Regions, Genetic | 1 | 1998 | 5789 | 0.000 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1989 | 543 | 0.000 |
Why?
|